Related Experiment Videos
Hydronephrosis in advanced ovarian carcinoma
1Department of Oncology B, Finsen Institute, Copenhagen, Denmark.
Gynecologic Oncology
|October 1, 1989
Summary
Hydronephrosis, a common complication in advanced ovarian carcinoma, significantly impacts survival. Patients with hydronephrosis at chemotherapy initiation face shorter survival rates compared to those without this condition.
Area of Science:
- Oncology
- Nephrology
- Radiology
Background:
- Hydronephrosis is a recognized complication in advanced ovarian carcinoma.
- Its occurrence and impact on renal function and survival in patients undergoing chemotherapy require further elucidation.
Purpose of the Study:
- To investigate the incidence and characteristics of hydronephrosis in patients with advanced ovarian carcinoma receiving combination chemotherapy.
- To assess the association between hydronephrosis and renal function, and its impact on patient survival.
Main Methods:
- Retrospective analysis of 232 patients with ovarian carcinoma (FIGO IIB-IV) undergoing combination chemotherapy.
- Diagnosis of hydronephrosis using intravenous pyelography or abdominal ultrasound.
- Assessment of renal function via serum creatinine and 51Cr-EDTA clearance.
Main Results:
- Hydronephrosis was observed in 22% of patients, predominantly in advanced stages (IIIB-IV) and with larger residual tumors (>2 cm).
- Unilateral hydronephrosis occurred in 77% of affected patients.
- Impaired renal function developed in 17% of patients with hydronephrosis.
- While early vs. late or unilateral vs. bilateral hydronephrosis did not affect survival, its presence at chemotherapy start was linked to significantly shorter survival (P < .05).
Conclusions:
- Hydronephrosis is a frequent complication in advanced ovarian cancer patients.
- The presence of hydronephrosis at the initiation of chemotherapy is a negative prognostic factor for survival in this patient group.